Cardiac Tolerability of Concurrent Administration of Trastuzumab and Anthracycline-Based Regimen as Adjuvant Chemotherapy for Breast Cancer

Breast care

Naoki Watanabe¹  Yoko Sasaki¹  Reiko Shimojima¹  Yoji Wani¹  Kaori Uchino¹  Shoko Otsuka¹ 

[1] aDepartment of Breast Surgery, Japanese Red Cross Society Himeji Hospital Hyogo, Japan

关键词: Anthracyclines;    Trastuzumab;    Cardiotoxicity;    Adjuvant chemotherapy;    Breast cancer;   

DOI  :  10.1159/000358754

学科分类：泌尿医学

来源: S Karger AG

【 摘 要 】

Retrospective analysis suggests that anthracycline-containing regimens may be superior to non-anthracycline-containing regimens in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer. However, both trastuzumab and anthracycline have cardiotoxicity, and it remains unclear how to use trastuzumab in combination with an anthracycline to curtail their cardiotoxicity.

【 授权许可】

Unknown